eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
eXoZymes, Inc.NASDAQ: EXOZ
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $74.15K rose 5.2% year over year, ahead of the -98.7% change in trailing-twelve-month cost of revenue.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.2% holds above the trailing-twelve-month pace of -98.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 267.38K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 147.75K | +148.7% |
| FY2021 | 2021-12-31 | 59.41K | — |
Cost of Revenue vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -98.7% is the lowest of 5, against a peer median of -79.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $234K USD | — | — | — | |
| LTM Mar 2026 | $129K USD | — | — | — | |
| LTM Mar 2026 | CA$119.31K CAD | -26.6% | -38.5% | — | |
| LTM Mar 2026 | $65K USD | -83.2% | -45.2% | 0.9% | |
| LTM Mar 2026 | $24K USD | -96.8% | -55.3% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $3.64K USD | -98.7% | — | — |
| LTM Mar 2026 | $876 USD | -75.7% | -21.0% | — | |
| Peer median (excluding EXOZ) | — | -79.5% | -41.9% | 0.9% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 59.41K | 147.75K | 0 | 267.38K | 0 |
| Gross Profit | (59.41K) | (147.75K) | 0 | (267.38K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 454.45K | 348.08K | 527.48K | 1.87M | 3.71M |
| Selling, General & Admin | 778.99K | 836.83K | 1.34M | 3.8M | 5.91M |
| Operating Expenses | 1.23M | 1.18M | 1.8M | 5.66M | 9.72M |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | 287.96K |
| EBITDA | (1.15M) | (1.18M) | (1.8M) | (5.59M) | (8.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.29M) | (1.33M) | (1.8M) | (5.93M) | (9.72M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 98 | 100 | 77.61K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 83.74K | 98 | (199.9K) | 70.77K | 452.53K |
| Income Before Tax | (1.21M) | (1.33M) | (2M) | (5.86M) | (9.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 63.56K | 42.27K | 0 | (105.21K) |
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| EPS (Diluted) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| Weighted Avg Shares | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
| Weighted Avg Shares (Diluted) | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.